Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report | Zendy

Luı́s Monteiro | Zendy; Cristiana Vasconcelos | Zendy; José Pacheco | Zendy; Filomena Salazar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report

Author(s) -

Luı́s Monteiro,

Cristiana Vasconcelos,

José Pacheco,

Filomena Salazar

Publication year - 2021

Publication title -

journal of clinical and experimental dentistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.481

H-Index - 23

ISSN - 1989-5488

DOI - 10.4317/jced.58323

Subject(s) - medicine , osteonecrosis of the jaw , lenvatinib , adverse effect , dentistry , denosumab , surgery , bisphosphonate , thyroid , thyroid cancer , osteoporosis

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction often presenting as a post-surgery complication that may interfere in the quality of the patient's life. In the last decade, additionally to bisphosphonates, other drugs have been associated with MRONJ including other antiresorptive, antiangiogenic or multitarget drugs such as levantinib. The data on MRONJ associated to lenvatinib is scarce with no guidelines for best management option. Our aim is to report a case of MRONJ associated with lenvatinib and the useful of a non-invasive management using local photobiomodulation (PBM) therapy with a 635nm diode laser.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research